Literature DB >> 16809477

The antidepressant -like effects of delta-opioid receptor agonists.

Emily M Jutkiewicz1.   

Abstract

Activation of the delta-opioid receptor (DOR) system produces an interesting behavioral profile distinct from that of other opioids. Unlike mu- and kappa-opioid agonists, delta-opioid agonists alone have limited pain-relieving qualities as measured in morphine-sensitive antinociceptive assays. Recent evidence, however, suggests that the DOR system may play a role in regulating mood and emotional states. For example, DOR activation stimulates robust antidepressant-like effects in preclinical assays, suggesting that these compounds may have therapeutic potential for treating human depression. This review discusses the role of the DORs in depression and the antidepressant-like effects of delta-opioid agonists as well as their limitations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16809477     DOI: 10.1124/mi.6.3.7

Source DB:  PubMed          Journal:  Mol Interv        ISSN: 1534-0384


  39 in total

1.  Endogenous opioids as physiological antidepressants: complementary role of δ receptors and dopamine.

Authors:  Emily M Jutkiewicz; Bernard P Roques
Journal:  Neuropsychopharmacology       Date:  2012-01       Impact factor: 7.853

Review 2.  Delta opioid receptor analgesia: recent contributions from pharmacology and molecular approaches.

Authors:  Claire Gavériaux-Ruff; Brigitte Lina Kieffer
Journal:  Behav Pharmacol       Date:  2011-09       Impact factor: 2.293

3.  Effects of delta opioid receptors activation on a response inhibition task in rats.

Authors:  Katia Befort; Megan K Mahoney; Carmen Chow; Scott J Hayton; Brigitte L Kieffer; Mary C Olmstead
Journal:  Psychopharmacology (Berl)       Date:  2010-12-23       Impact factor: 4.530

4.  Novel sigma (sigma) receptor agonists produce antidepressant-like effects in mice.

Authors:  Jiajia Wang; Aisha L Mack; Andrew Coop; Rae R Matsumoto
Journal:  Eur Neuropsychopharmacol       Date:  2007-03-21       Impact factor: 4.600

5.  Discovery, synthesis, and molecular pharmacology of selective positive allosteric modulators of the δ-opioid receptor.

Authors:  Neil T Burford; Kathryn E Livingston; Meritxell Canals; Molly R Ryan; Lauren M L Budenholzer; Ying Han; Yi Shang; John J Herbst; Jonathan O'Connell; Martyn Banks; Litao Zhang; Marta Filizola; Daniel L Bassoni; Tom S Wehrman; Arthur Christopoulos; John R Traynor; Samuel W Gerritz; Andrew Alt
Journal:  J Med Chem       Date:  2015-05-07       Impact factor: 7.446

Review 6.  Salvinorin A analogs as probes in opioid pharmacology.

Authors:  Thomas E Prisinzano; Richard B Rothman
Journal:  Chem Rev       Date:  2008-05       Impact factor: 60.622

7.  Design, Synthesis, and Biological Evaluation of the Third Generation 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan (NAP) Derivatives as μ/κ Opioid Receptor Dual Selective Ligands.

Authors:  Yi Zheng; Samuel Obeng; Huiqun Wang; Abdulmajeed M Jali; Bharath Peddibhotla; Dwight A Williams; Chuanchun Zou; David L Stevens; William L Dewey; Hamid I Akbarali; Dana E Selley; Yan Zhang
Journal:  J Med Chem       Date:  2019-01-11       Impact factor: 7.446

8.  Behavioral and cellular pharmacology characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) as a mu opioid receptor selective ligand.

Authors:  Yan Zhang; Amanda Braithwaite; Yunyun Yuan; John M Streicher; Edward J Bilsky
Journal:  Eur J Pharmacol       Date:  2014-05-08       Impact factor: 4.432

9.  In vitro and in vivo pharmacological profile of UFP-512, a novel selective delta-opioid receptor agonist; correlations between desensitization and tolerance.

Authors:  B Aguila; L Coulbault; M Boulouard; F Léveillé; A Davis; G Tóth; A Borsodi; G Balboni; S Salvadori; P Jauzac; S Allouche
Journal:  Br J Pharmacol       Date:  2007-11-05       Impact factor: 8.739

10.  Cocaine withdrawal-induced anxiety in females: impact of circulating estrogen and potential use of delta-opioid receptor agonists for treatment.

Authors:  Lisa M Ambrose-Lanci; R C Sterling; Elisabeth J Van Bockstaele
Journal:  J Neurosci Res       Date:  2010-03       Impact factor: 4.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.